STK11 and breast carcinoma: Germline mutations in breast cancer 1 (BRCA1), breast cancer 2 (BRCA2), ataxia telangiectasia mutated (ATM), partner and localizer of BRCA2 (PALB2), cyclin-dependent kinase inhibitor 2A (CDKN2A), tumor protein p53 (TP53), serine/threonine kinase 11 (STK11), and mismatch repair genes (MLH1, MSH2, MSH6, PMS2) significantly increase PDAC risk.